Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide

The Key Aspergillosis Companies in the market include - Astellas Pharma/ Basilea Pharmaceutica International, F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide, Sanofi, and others.

The Aspergillosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aspergillosis pipeline products will significantly revolutionize the Aspergillosis market dynamics.

DelveInsight's "Aspergillosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Aspergillosis, historical and forecasted epidemiology as well as the Aspergillosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Aspergillosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Aspergillosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aspergillosis Market Insights [https://www.delveinsight.com/sample-request/aspergillosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Aspergillosis Market Report:

*
The Aspergillosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In June 2024, New York-based biotech company Elion Therapeutics secured $81 million in Series B funding to advance its early-stage polyene antifungal therapy, SF001. The therapy is being developed as an initial treatment for presumed invasive fungal disease and invasive aspergillosis. In 2023, SF001 received Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA. After completing a first-in-human single-ascending dose study, the drug has now progressed to a multiple-ascending dose study.

*
The Aspergillosis market in the US was valued at approximately USD 1,125 million in 2023 and is expected to grow at an estimated compound annual growth rate (CAGR) of 10% during the forecast period.

*
In 2023, the Aspergillosis market in the EU4 and the UK was valued at around USD 866 million and is projected to experience a significant compound annual growth rate (CAGR) throughout the forecast period.

*
In 2023, the UK held the largest market size for Aspergillosis among EU countries, with approximately USD 325 million, while Spain reported the smallest market size, around USD 110 million.

*
The anticipated introduction of new therapies, including Opelconazole (PC945) and Olorofim, is expected to drive significant changes in the overall market size of Aspergillosis in the coming years.

*
In April 2024, Pulmocide Ltd. announced encouraging topline results from the OPERA-S study, a Phase II trial assessing inhaled opelconazole in lung transplant recipients. The findings showed that opelconazole was well tolerated, with fewer adverse events and drug-drug interactions compared to standard treatments, successfully preventing and eliminating pulmonary Aspergillus and Candida infections.

*
In January 2024, TFF Pharmaceuticals revealed that it will present Phase II trial results for Voriconazole Inhalation Powder (TFF VORI) in the treatment of invasive pulmonary aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference in Milan, Italy, highlighting progress in combating this serious fungal infection.

*
In 2023, the US recorded approximately 568 thousand prevalent cases of aspergillosis, with allergic bronchopulmonary aspergillosis (ABPA) accounting for 92% of the cases, while chronic pulmonary aspergillosis (CPA) made up just 2%. Both conditions are anticipated to experience growth in prevalence during the forecast period.

*
In 2023, the UK accounted for a large portion of diagnosed prevalent cases of aspergillosis among the EU4 and the UK, with around 179 thousand cases, while Spain reported the fewest cases, approximately 67 thousand. This contrast emphasizes the UK's dominant position in the regional aspergillosis landscape compared to Spain's lower case numbers.

*
DelveInsight's estimates show a notable difference in aspergillosis types in Japan, with ABPA representing nearly 334 thousand cases, while Invasive Aspergillosis accounts for just around 4,419 cases out of a total of 343 thousand, highlighting a clear type-specific variation in diagnosed prevalence.

*
Key Aspergillosis Companies: Astellas Pharma/ Basilea Pharmaceutica International, F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide, Sanofi, and others

*
Key Aspergillosis Therapies: CRESEMBA, Olorofim, Pulmazole (PUR1900), Voriconazoledry-powder inhalation (TFFVORI), Ibrexafungerp, PC945, Dupilumab, and others

*
The Aspergillosis epidemiology based on gender analyzed that among the types of aspergillosis, ABPA patient population is highest mainly due to occurrence in larger population of Asthma and Cystic fibrosis

Aspergillosis Overview

Aspergillosis is an infection or allergic reaction that is caused by the aspergillus fungus, which is commonly found in the environment. There are various types of aspergillosis but the major ones are chronic pulmonary aspergillosis (CPA), invasive aspergillosis (IA) and allergic bronchopulmonary aspergillosis (ABPA). The symptoms of aspergillosis can vary depending upon the specific form of the disorder present

Get a Free sample for the Aspergillosis Market Report

https://www.delveinsight.com/sample-request/aspergillosis-market [https://www.delveinsight.com/sample-request/aspergillosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Aspergillosis Market

The dynamics of the Aspergillosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Aspergillosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Aspergillosis Epidemiology Segmentation:

The Aspergillosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Aspergillosis

*
Prevalent Cases of Aspergillosis by severity

*
Gender-specific Prevalence of Aspergillosis

*
Diagnosed Cases of Episodic and Chronic Aspergillosis

Download the report to understand which factors are driving Aspergillosis epidemiology trends @ Aspergillosis Epidemiological Insights [https://www.delveinsight.com/sample-request/aspergillosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Aspergillosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aspergillosis market or expected to get launched during the study period. The analysis covers Aspergillosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Aspergillosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Aspergillosis Therapies and Key Companies

*
CRESEMBA: Astellas Pharma/ Basilea Pharmaceutica International

*
Olorofim: F2G

*
Pulmazole (PUR1900): Pulmatrix

*
Voriconazoledry-powder inhalation (TFFVORI): TFF Pharmaceuticals

*
Ibrexafungerp: Scynexis

*
PC945: Pulmocide

*
Dupilumab: Sanofi

To know more about Aspergillosis treatment, visit @ Aspergillosis Medications [https://www.delveinsight.com/sample-request/aspergillosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Aspergillosis Market Drivers

*
Research and development strategies

*
Increasing Burden of various forms of Aspergillosis

*
Combination of antifungal agents against invasive aspergillosis

Aspergillosis Market Barriers

*
Availability of generics and off-label therapies

*
Lack of accurate diagnosis

Scope of the Aspergillosis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Aspergillosis Companies: Astellas Pharma/ Basilea Pharmaceutica International, F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide, Sanofi, and others

*
Key Aspergillosis Therapies: CRESEMBA, Olorofim, Pulmazole (PUR1900), Voriconazoledry-powder inhalation (TFFVORI), Ibrexafungerp, PC945, Dupilumab, and others

*
Aspergillosis Therapeutic Assessment: Aspergillosis current marketed and Aspergillosis emerging therapies

*
Aspergillosis Market Dynamics: Aspergillosis market drivers and Aspergillosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Aspergillosis Unmet Needs, KOL's views, Analyst's views, Aspergillosis Market Access and Reimbursement

Discover more about therapies set to grab major Aspergillosis market share @ Aspergillosis Treatment Landscape [https://www.delveinsight.com/sample-request/aspergillosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Aspergillosis Market Report Introduction

2. Executive Summary for Aspergillosis

3. SWOT analysis of Aspergillosis

4. Aspergillosis Patient Share (%) Overview at a Glance

5. Aspergillosis Market Overview at a Glance

6. Aspergillosis Disease Background and Overview

7. Aspergillosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Aspergillosis

9. Aspergillosis Current Treatment and Medical Practices

10. Aspergillosis Unmet Needs

11. Aspergillosis Emerging Therapies

12. Aspergillosis Market Outlook

13. Country-Wise Aspergillosis Market Analysis (2020-2034)

14. Aspergillosis Market Access and Reimbursement of Therapies

15. Aspergillosis Market Drivers

16. Aspergillosis Market Barriers

17. Aspergillosis Appendix

18. Aspergillosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aspergillosis-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-f2g-pulmatrix-tff-pharmaceuticals-scynexis-pulmocide]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.